

LIBRARY COPY

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 33/06, 39/09, 39/10, 39/155, 39/145, 39/20		A2	(11) International Publication Number: WO 95/34308 (43) International Publication Date: 21 December 1995 (21.12.95)
(21) International Application Number: PCT/CA95/00359		(74) Agent: STEWART, Michael, I.; Sim & McBurney, Suite 701, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).	
(22) International Filing Date: 15 June 1995 (15.06.95)			
(30) Priority Data: 08/261,194 16 June 1994 (16.06.94)		US	(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(60) Parent Application or Grant (63) Related by Continuation US Filed on		08/261,194 (CON) 16 June 1994 (16.06.94)	
(71) Applicant (for all designated States except US): CANNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, Willowdale, Ontario M2R 3T4 (CA).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): KANDIL, Ali [CA/CA]; 245 Park Home Avenue, Willowdale, Ontario M2R 1A1 (CA). JAMES, Olive, A. [CA/CA]; Apartment 609, 10 Martha Eaton Way, Toronto, Ontario M6M 5B3 (CA). CHONG, Pele [CA/CA]; 32 Estoril Street, Richmond Hill, Ontario L4C 0B6 (CA). KLEIN, Michel, H. [CA/CA]; 16 Munro Boulevard, Willowdale, Ontario M2P 1B9 (CA).			
(54) Title: ADJUVANT COMPOSITIONS COMPRISING A MINERAL SALT AND ANOTHER IMMUNOSTIMULATING COMPOUND			
(57) Abstract			
<p>Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an adjuvanting effect on an antigen which is greater than the adjuvanting effect attainable by one of the adjuvants alone. An antigen is covalently bonded to a glycolipid analog to provide a discrete molecule which exhibits an enhanced adjuvanting effect on the antigen which is greater than the adjuvanting effect attainable in the absence of such covalent bonding.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TITLE OF THE INVENTION

ADJUVANT COMPOSITIONS COMPRISING A MINERAL SALT AND ANOTHER IMMUNOSTIMULATING COMPOUND

FIELD OF THE INVENTION

5 The present invention relates to the field of immunology and is particularly concerned with adjuvants, i.e. materials which modulate immune response to an antigen.

BACKGROUND OF THE INVENTION

10 Vaccines have been used for many years to protect humans and animals against a wide variety of infectious diseases. Such conventional vaccines consist of attenuated pathogens (for example, polio virus), killed pathogens (for example, Bordetella pertussis) or 15 immunogenic components of the pathogen (for example, diphtheria toxoid). Some antigens are highly immunogenic and are capable alone of eliciting protective immune responses. Other antigens, however, fail to induce a protective immune response or induce only a weak immune 20 response.

In the development of some vaccines and immunogenic compositions, there is a trend to use smaller and well defined immunogenic and protective materials. Recent advances in molecular genetics, protein biochemistry, 25 peptide chemistry, and immunobiology have provided economical and efficient technologies to identify and produce large quantities of pure antigens from various pathogens. However, some such materials may not be sufficiently immunogenic, due to either their small size 30 (especially synthetic peptides) or the lack of intrinsic immunostimulatory properties thereof.

Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants. Adjuvants enhance the immunogenicity of an antigen but are not 35 necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a

slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

5 Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines.

10 Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered parenterally. Some of

15 these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in

20 human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well established and, more recently, a HBsAg vaccine has been adjuvanted with alum. While the usefulness of alum is well established for some

25 applications, it has limitations. For example, alum is ineffective for influenza vaccination and inconsistently elicits a cell mediated immune response. The antibodies elicited by alum-adjuvanted antigens are mainly of the IgG1 isotype in the mouse, which may not be optimal for

30 protection by some vaccinal agents.

35 A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl

dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

To efficiently induce humoral immune responses (HIR) and cell-mediated immunity (CMI), immunogens are 5 emulsified in adjuvants. Many adjuvants are toxic, inducing granulomas, acute and chronic inflammations (Freund's complete adjuvant, FCA), cytolysis (saponins and Pluronic polymers) and pyrogenicity, arthritis and 10 anterior uveitis (LPS and MDP). Although FCA is an excellent adjuvant and widely used in research, it is not licensed for use in human or veterinary vaccines because 15 of its toxicity.

Desirable characteristics of ideal adjuvants include:

- 15 (1) lack of toxicity;
- (2) ability to stimulate a long-lasting immune response;
- (3) simplicity of manufacture and stability in long-term storage;
- (4) ability to elicit both CMI and HIR to antigens 20 administered by various routes, if required;
- (5) synergy with other adjuvants;
- (6) capability of selectively interacting with populations of antigen presenting cells (APC);
- (7) ability to specifically elicit appropriate T_{H1} or T_{H2} 25 cell-specific immune responses; and
- (8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens.

US Patent No. 4,855,283 granted to Lockhoff et al on August 8, 1989 teaches glycolipid analogues including N- 30 glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvants. Thus, Lockhoff et al. (US Patent No. 4,855,283) reported that N-glycolipid analogs displaying structural similarities 35 to the naturally-occurring glycolipids, such as glycosphingolipids and glycoglycerolipids, are capable of

eliciting strong immune responses in both herpes simplex virus vaccine and pseudorabies virus vaccine. Some glycolipids have been synthesized from long chain-alkylamines and fatty acids that are linked directly with 5 the sugars through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.

U.S. Patent No. 4,258,029 granted to Moloney, assigned to the assignee hereof, teaches that octadecyl tyrosine hydrochloride (OTH) functioned as an adjuvant 10 when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Also, Nixon-George et al. (1990), J. Immunology 144:4798-4802 reported that octadecyl esters of aromatic 15 amino acids complexed with a recombinant hepatitis B surface antigen, enhanced the host immune responses against hepatitis B virus.

Lipidation of synthetic peptides has also been used to increase their immunogenicity. Thus, Wiesmuller ((1989), Vaccine 8:29-33) describes a peptide with a 20 sequence homologous to a foot-and-mouth disease viral protein coupled to an adjuvant tripalmitoyl-S-glyceryl-cysteinylserylserine, being a synthetic analogue of the N-terminal part of the lipoprotein from Gram negative bacteria. Furthermore, Deres et al. (1989, Nature 25 342:561) reported in vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine which comprised of modified synthetic peptides derived from influenza virus nucleoprotein by linkage to a lipopeptide, N-palmitoyl-S-[2,3-bis(palmitoylxy)-(2RS)-30 propyl-[R]-cysteine (TPC).

The adjuvants and immunostimulating compounds described above may not provide for adjuvanticity for all antigens delivered to a variety of hosts under many conditions.

It would be desirable to provide adjuvant compositions that do not suffer from the disadvantages and limitations of currently available adjuvants.

SUMMARY OF INVENTION


5 The present invention is directed towards the provision of improved adjuvant compositions. In accordance with one aspect of the present invention, there is provided an adjuvant composition for modulating an immune response to an antigen administered to a host, 10 the composition comprising:

- (a) a mineral salt adjuvant; and
- (b) at least one other adjuvant.

15 The multiple adjuvant compositions provided herein exhibit a surprisingly unexpected adjuvanting effect on an antigen which is greater than the adjuvanting effect attainable by one of the adjuvants alone. The enhanced effect may be additive of the adjuvanting effect of the individual adjuvants and, in particular embodiments, a synergistic effect is attained.

20 The mineral salt adjuvant preferably comprises aluminum hydroxide or aluminum phosphate, although other known mineral salt adjuvants, such as calcium phosphate, zinc hydroxide or calcium hydroxide, may be used. The at least one other adjuvant may be a glycolipid analog, an octadecyl ester of an amino acid (such as an aromatic amino acid) or a lipoprotein. The lipoprotein may be a 25 synthetic analogue of an N-terminal portion of lipoprotein.

30 In a particular embodiment, the glycolipid may be a glycosylamide and may have the formula:



wherein R1 denotes hydrogen or saturated or singly or multiply unsaturated alkyl radical having up to 50 carbon atoms;

X represents -CH₂-, -O- or -NH-;

5 R2 denotes hydrogen or a saturated or singly or multiply unsaturated alkyl radical having up to 50 carbon atoms, R3, R4, and R5, independently of one another, denotes hydrogen, or SO₄²⁻, or PO₄²⁻, or other negatively charged moiety, or -CO-R6, R6 being an alkyl radical having up to
10 carbon atoms;

R7 is L-alanyl, L-alpha-aminobutyryl, L-arginyl, L-asparginyl, L-aspartyl, L-cysteinyl, L-glutamyl, L-glycyl, L-histidyl, L-hydroxypropyl, L-isoleucyl, L-leucyl, L-lysyl, L-methionyl, L-ornithinyl, L-phenylalanyl, L-prolyl, L-seryl, L-threonyl, L-tyrosyl, L-tryptophanyl, and L-lavyl or their D-isomers; and pharmaceutically acceptable salts thereof. In an embodiment, the glycosylamide may be N - (2-deoxy-2-L-leucylamino- β -D-glucopyranosyl) - N - octadecyldodecanamide acetate.

In accordance with a further aspect of the present invention, there is provided an immunogenic composition for eliciting an immune response in a host, including a human, the composition comprising:

25 (a) at least one antigen;
(b) a mineral salt adjuvant; and
(c) at least one other adjuvant.

In yet another aspect of the invention, there is provided a method of modulating an immune response to an
30 antigen comprising combining the antigen with the adjuvant composition of the present invention.

Convenient antigens which may be included in said immunogenic compositions and in respect of which an immune response is modulated, include microbial
35 pathogens, bacteria, viruses, proteins, glycoproteins lipoproteins, peptides, glycopeptides, lipopeptides,

toxoids, carbohydrates, and tumor-specific antigens. Mixtures of two or more antigens may be employed.

Such peptides, glycopeptides or lipopeptides may include an amino acid sequence corresponding to an 5 antigenic determinant of HIV, Rubella virus, Respiratory Syncytial Virus, Bordetella pertussis, Haemophilus influenzae or Streptococcus pneumoniae, including those specific synthetic peptides shown in Table I below (SEQ ID NOS: 1 to 15) (The Tables appear at end of the 10 descriptive text) or a functional analog thereof. The toxoid may be a pertussis toxoid while the protein may be influenza hemagglutinin or a parainfluenza virus subunit, such as the HN or F proteins of PIV-3.

In a further aspect of the invention, there is 15 provided a method of generating an immune response in a host, including a human, comprising administering thereto the immunogenic composition of the present invention. The immune response attained may be a humoral or a cell-mediated immune response.

20 In a particular aspect of the present invention, there is provided a kit for preparing an immunogenic composition, comprising:

- (a) means for containing a mineral salt adjuvant;
- (b) means for containing at least one other adjuvant;
- 25 (c) means for containing at least one antigen; and
- (d) means for combining the mineral salt adjuvant, at least one other adjuvant and at least one antigen to produce the immunogenic composition.

30 In a further aspect of the present invention, there is provided a compound comprising an antigen, including any of those referred to above, covalently linked to a glycolipid analog, such as a glycosylamide, as well as immunogenic compositions comprising the same for generating an immune response in a host, including a 35 human. The glycosylamide may have the formula I above.

By covalently bonding an antigen to a glycolipid analog, a discrete molecule is produced which exhibits a surprisingly unexpected enhanced adjuvanting effect on the antigen which is greater than the adjuvanting effect 5 attainable in the absence of such covalent bonding, as in a mixture of the two components. A further enhanced adjuvanting effect may be attained for such covalently-bonded antigen by incorporating a mineral salt adjuvant with such compounds.

10 The antigen may be covalently linked to the glycolipid analog at a carboxy or amino terminus or other suitable site compatible with covalent linkage of the antigen by, for example, a cross-linker having a reactive function, such as maleimidyl, succinimidyl, 2-pyridyldithio, NH₂, SH, and -CO-R8, where R8 is -OH, N₃, -O-alkyl(C₁-C₂), -OC₆F₅, H, Br, or Cl.

15 Advantages of the present invention include:
(a) ease of formulation;
(b) effectiveness of adjuvanticity; and
20 (c) compatibility of antigens with the adjuvant composition.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows antibody responses to HIV peptides in guinea pigs formulated with adjuvants according to one 25 embodiment of the invention;

Figure 2 shows antibody responses in guinea pigs to a cocktail of HIV peptides formulated with adjuvants according to an embodiment of the present invention;

30 Figure 3 shows haemagglutinin inhibition antibody responses in mice to a Human parainfluenza virus subunit vaccine formulated with adjuvants according to the present invention;

35 Figure 4 shows virus neutralization antibody responses to a Human parainfluenza virus subunit vaccine formulated with adjuvants according to the present invention;

Figure 5 shows guinea pig immune responses to a split influenza vaccine formulated with adjuvants according to an embodiment of the present invention against three influenza virus strains;

5 Figure 6 shows guinea pig immune responses (determined by anti-PT ELISA) to pertussis toxoid formulated with adjuvants according to an embodiment of the present invention;

10 Figure 7 shows guinea pig immune responses (determined by the CHO cell neutralizing assay) (Grunstrom et al. 1985 J. Infec. Dis. 151:646-649) to pertussis toxoid formulated with adjuvants according to an embodiment of the present invention;

15 Figure 8 shows a guinea pig immune response to an HIV peptide CLTB36 formulated with adjuvants or conjugated to BAY R1005 according to an embodiment of the present invention; and

20 Figure 9 shows guinea pig antibody responses to HIV peptide (CLTB 36) formulated with alum or conjugated to BAY R1005 according to an embodiment of the present invention.

GENERAL DESCRIPTION OF THE INVENTION

It will be apparent to those skilled in the art, that the various embodiments of the present invention 25 have many applications in the fields of medicine and, in particular, vaccination, diagnosis, generation of immunological agents, and treatment of infections with pathogens, including bacteria and viruses. A further non-limiting discussion of such uses is further presented 30 below.

As noted above, the present invention relates, in one aspect, to adjuvant compositions useful for modulating the immune response to an antigen.

35 Synthetic antigens, including vaccines, may be prepared by chemically synthesizing peptides sharing antigenic determinants with proteins, for example, of

HIV-1, rubella virus, RSV, Haemophilus influenzae type b, Bordetella pertussis and Streptococcus pneumoniae or other antigens. These peptides, lipid derivatives of such peptides as well as viral antigens or bacterial 5 antigens, may be used either individually or combined as a cocktail, and formulated with synthetic adjuvants and mineral salts to provide an immunogenic composition. These compositions can be used to immunize mammals, for example, by the intramuscular or parenteral routes, or by 10 delivery to mucosal surfaces using microparticles, capsules, liposomes and targeting molecules, such as toxins and antibodies.

Reference will now be made in detail to the presently preferred embodiments of the invention, which 15 together with the following Examples, help to explain the invention.

Antigen Selection

Several antigens were selected to exemplify the present invention. Advances in biotechnology now enable 20 bacterial and viral antigens to be identified and purified on a large scale. However, subunit or synthetic vaccine candidates are sometimes of low immunogenicity, due to their size (especially synthetic peptides) or the lack of intrinsic immunostimulatory properties. Thus, 25 external additives are often required to enhance their immunogenicity. Several antigens have been chosen which are able to elicit strong IgG antibody responses in adjuvants, such as CFA. The selected antigens include synthetic peptides (Table 1) sharing antigenic determinants with the proteins of HIV-1, rubella virus 30 (RV), respiratory syncytial virus (RSV), Haemophilus influenzae type b (Hib), Bordetella pertussis and Streptococcus pneumoniae, and the HN and F proteins from parainfluenza virus 3 (PIV3), pertussis toxoid and 35 chemically-disrupted influenza virus.

Synthetic Adjuvants

Synthetic adjuvants, such as glycolipid analogs (Lockhoff et al., US Patent No. 4,855,283), lipopeptide (Wiesmuller et al. (1989), Vaccine 8:29-33) and octadecyl ester of aromatic amino acids (Moloney et al., US Patent No. 4,258,029) have been shown to act as adjuvants to enhance the immunogenicity of viral and bacterial antigens. Therefore, three adjuvants, namely N-palmityl-S-[2,3-bis(palmityloxy)-(2RS)-propyl-[R]-cysteine (TPC, 10 Wiesmuller et al., Vaccine (1989) 8:29-33); N-(2-deoxy-2-L-leucylamino- β -D-glucopyranosyl)-N-octadecyldecanamide acetate (BAY R1005, O. Lockhoff, Angew. Chem. Int. Ed. Engl. (1991) 30:1611-1620); and octadecyl-tyrosine (OTH) (Nixon-George et al. (1990), J. Immunology 144:4798-4802) 15 were selected as starting molecules for designing more potent synthetic adjuvant compositions. These three classes of synthetic adjuvants were synthesized and characterized. The synthesis of the three classes of adjuvants required less than ten steps of reaction. The 20 protocols for the adjuvant synthesis are well established and reported in the literature. Scale-up production for BAY R1005 and octadecyl-tyrosine would be within the skill of the art.

All three classes of synthetic adjuvant are 25 insoluble in water or aqueous buffer, such as phosphate buffered saline (PBS). They form a milky solution when mixed with water or aqueous buffer. They are non-toxic, as judged by a lack of adverse reactions in mice injected with 1 to 2 mg, and non-pyrogenic in a rabbit pyrogen 30 test. All three classes of synthetic adjuvant are very stable in powdered form at -20°C and can be suspended into aqueous buffer for long term storage at 4°C.

To analyse the effectiveness of the synthetic adjuvants, 100 μ g of synthetic peptides (Table 1) 35 containing known functional T-helper and B-cell epitopes were used as antigens. Fifteen peptides, including

epitopes from HIV-1, RSV, Rubella virus, H. influenzae, B. pertussis, and S. pneumoniae, were individually injected intramuscularly into guinea pigs, either in the presence of FCA, or alum (aluminium phosphate), or TPC, or BAY R1005, or OTH or PBS. The effect of adjuvants on antibody responses were evaluated using peptide-specific ELISAs. As shown in Table 2 below, all peptides emulsified in FCA elicited strong antibody responses, whereas peptides in PBS either elicited very low anti-peptide titer or failed to elicit any detectable antibody response. After three immunizations, the fifteen peptides absorbed onto alum were capable of inducing peptide-specific IgG antibody responses. Only two peptides (RV-EP27 and PSP-AA) in the presence of BAY R1005, failed to elicit significant antibody responses after three immunizations. One of the peptides (RV-EP27) that failed to elicit significant antibody responses in BAY R1005, was highly immunogenic and induced peptide-specific antibody response when TPC was used as adjuvant. In most cases, both synthetic adjuvants, TPC and OTH, enhanced the immunogenicity of the peptide, but the reactive titers were much lower than those obtained from alum or CFA. These results are consistent with published data reported by other workers, and demonstrate the adjuvant potential of the synthetic adjuvants and the capacity of these peptides to be adjuvanted.

In one aspect, the present invention provides an adjuvant composition for modulating an immune response to an antigen administered to a host, the composition comprising a mineral salt adjuvant and at least one other adjuvant. To exemplify this aspect of the invention, several HIV-1 peptides were used in guinea pig immunogenicity studies. Peptides were absorbed onto alum first and then emulsified with the synthetic adjuvant before injecting into different groups of guinea pigs. Guinea pigs were also immunized either with peptides

absorbed onto alum, or peptides emulsified with synthetic adjuvant, as controls. The antibody response results obtained with the synthetic adjuvant BAY R1005 are shown in Fig. 1. No adverse reactions were seen in any of the 5 guinea pigs. It was surprisingly found, according to the present invention, that alum (3 mg/mL) combined with a synthetic adjuvant (BAY R1005 (1 mg/mL)) resulted in increased anti-peptide antibody responses after two immunizations in comparison to those titers produced by 10 the same peptide using either synthetic adjuvant or mineral salts alone as adjuvant. These studies thus indicate that the immune response to an antigen that has already been enhanced by adsorption to alum under standard conditions can unexpectedly be further enhanced 15 by another adjuvant, according to the present invention.

The unexpected immune response enhancing capacity of adjuvant compositions of the present invention was further demonstrated for synthetic peptides RSV-F and RV-EP27 (Table 1). When these peptides were adjuvanted with 20 alum alone, antibody titres of 32000 (RSV-F) and 12800 (RV-EP27) were obtained (Table 3). When the same peptides were adjuvanted with BAY R1005, they were poorly immunogenic. However, when these peptides were adjuvanted with an adjuvant composition comprising alum 25 and BAY R1005, antibody titres of 128,000 (RSV-F) and 64000 (RV-EP27) were obtained. These results thus show the capacity of this adjuvant composition to enhance the immune response to an antigen beyond that obtainable by either individual adjuvant. In fact, an immune response 30 was obtained that was more than the sum of the immune response to each of the adjuvants individually, i.e. a synergistic effect was obtained.

To further assess the adjuvant effect of the present invention, the HN and F glycoproteins from parainfluenza 35 virus 3 (PIV3) were absorbed first onto alum and then emulsified with BAY R1005 before injecting

intraperitoneally (i.p.) to CD1 mice. As controls, the same antigens were either absorbed onto alum, or emulsified with BAY R1005, or mixed with PBS and then used to immunize i.p. groups of CD1 mice. No adverse 5 reactions were seen in any of the mice. It was surprisingly found that the primary antibody responses to HN and F were best with the alum/BAY R1005 adjuvant composition. The functional antibody responses as measured by haemagglutinin inhibition and virus 10 neutralization assays, revealed that mice immunized with antigen formulated with an adjuvant composition of the present invention generated higher antibody levels than obtained with a single adjuvant (Figs. 3 and 4).

To determine whether the steps of formulation would 15 affect the adjuvant effects of the compositions of the present invention, commercially-available split flu vaccine was first emulsified with BAY R1005 (1 mg/mL) and then absorbed onto alum (3 mg/mL) before injecting intraperitoneally (i.p.) into mice. As controls, the 20 same preparation was either absorbed onto alum, or emulsified with BAY R1005, or mixed with PBS and then was used to immunize different groups of mice. Again, no adverse reactions were seen in any of the groups of mice. The BAY R1005/alum combination adjuvant formulation gave 25 the best anti-HA antibody responses (Fig. 5) against various influenza strains.

The results obtained with the split flu vaccine indicate that the sequence of steps used to formulate the antigen with the different adjuvants is not material to 30 the adjuvanting effect obtained.

The adjuvant compositions of the present invention were also able to modulate the immune response to gluteraldehyde-inactivated pertussis toxoid. Thus, guinea pigs were immunized with pertussis toxoid in alum 35 alone, BAY R1005 or BAY R1005 anti-PT and toxin neutralizing antibody titres determined (Figures 6 and

7). The results presented indicate that the highest (and a synergistic) immune response was obtained when the pertussis toxoid was formulated with alum and BAY R1005 according to the present invention.

5 **Immunogenicity of Peptides Covalently Linked to Synthetic Adjuvants**

The task of providing a synthetic peptide as a self-sufficient immunogen capable of eliciting both humoral and cell-mediated immune responses, is very challenging.

10 To determine whether a peptide antigen covalently linked to an adjuvant can elicit both humoral and cell-mediated immune responses, peptide CLTB-36 was synthesized with synthetic adjuvant BAY R1005 covalently linked at the N-terminus. During the preparation of the CLTB-36 covalently linked with BAY R1005, it may be desirable to use Fmoc peptide synthesis chemistry and temporarily protect reactive functional groups, for example, alcohols by t-butyl and acids by ester groups. Suitable protection-deprotection conditions and protocols are 15 described in Examples herein. The peptide-adjuvant conjugate was purified by RP-HPLC and used to immunize guinea pigs. These immunogenicity studies revealed that CLTB-36 covalently linked to BAY R1005 was as immunogenic as CLTB-36 formulated with (BAY R1005 + alum) (Figures 8, 20 9 and Table 4). The anti-CLTB-36 antibody titer obtained was about 3-fold and 20-fold higher than those elicited either in the presence of BAY R1005 or alum, respectively (Fig. 8). In addition, the peptide-adjuvant conjugate (BAY-CLTB-36) required fewer immunizations and less 25 antigen to elicit the same degree of anti-peptide antibody responses as shown in Figure 9. These results show that an antigen with a built-in immunomodulator can induce strong immune responses.

Vaccine preparation and use

30 As indicated above, the present invention, in one embodiment, provides adjuvant mixtures useful for

formulating immunogenic compositions, suitable to be used as, for example, vaccines. The immunogenic composition elicits an immune response by the host to which it is administered including the production of antibodies by

5 the host. The immunogenic compositions include at least one antigen in one embodiment. This antigen may be an inactivated pathogen or an antigenic fraction of a pathogen. The pathogen may be, for example, a virus, a bacterium or a parasite. The pathogen may be inactivated

10 by a chemical agent, such as formaldehyde, glutaraldehyde, β -propiolactone, ethyleneimine and derivatives, or other compounds. The pathogen may also be inactivated by a physical agent, such as UV radiation, gamma radiation, "heat shock" and X-ray radiation.

15 An antigenic fraction of a pathogen can be produced by means of chemical or physical decomposition methods, followed, if desired, by separation of a fraction by means of chromatography, centrifugation and similar techniques. In general, low molecular components are

20 then obtained which, although purified, may have low immunogenicity. Alternatively, antigens or haptens can be prepared by means of organic synthetic methods, or, in the case of, for example, polypeptides and proteins, by means of recombinant DNA methods.

25 Vaccines containing peptides are generally well known in the art, as exemplified by U.S. Patents 4,601,903; 4,599,231; 4,599,230; and 4,596,792; all of which references are incorporated herein by reference.

30 The use of peptides in vivo may first require their chemical modification since the peptides themselves may not have a sufficiently long serum and/or tissue half-life and/or sufficient immunogenicity.

35 For this purpose, the molecule of the invention may optionally be linked to a carrier molecule. Many suitable linkages are known, e.g., using the side chains of the Tyr residues. Suitable carriers include, e.g.,

keyhole limpet hemocyanin (KLH), serum albumin, purified protein derivative of tuberculin (PPD), ovalumin, non-protein carriers and many others.

In addition, it may be advantageous to modify the 5 peptides in order to impose a conformational restraint upon them. This might be useful, for example, to mimic a naturally-occurring conformation of the peptide in the context of the native protein in order to optimize the effector immune responses that are elicited.

10 Modified peptides are referred to herein as "peptide analogs". The term "peptide analog" extends to any functional chemical equivalent of a peptide characterized by its increased stability and/or efficacy and immunogenicity in vivo or in vitro in respect of the 15 practice of the invention. The term "peptide analog" is also used herein to extend to any amino acid derivative of the peptides as described herein. Peptide analogs contemplated herein are produced by procedures that include, but are not limited to, modifications to side 20 chains, incorporation of unnatural amino acids and/or their derivatives during peptide synthesis and the use of cross-linkers and other methods which impose conformational constraint on the peptides or their analogs.

25 It will be apparent that the peptides employed herein as antigens can be modified in a variety of different ways without significantly affecting the functionally important immunogenic behaviour thereof. Possible modifications to the peptide sequence may 30 include the following:

One or more individual amino acids can be substituted by amino acids having comparable or similar properties, thus:

V may be substituted by I;

35 T may be substituted by S;

K may be substituted by R; or

L may be substituted by I, V or M.

One or more of the amino acids of peptides of the invention can be replaced by a "retro-inverso" amino acid, i.e., a bifunctional amine having a functional group corresponding to an amino acid, as discussed in published International application WO 91/13909.

One or more amino acids can be deleted.

Structural analogs mimicking the 3-dimensional structure of the peptide can be used in place of the peptide.

Examples of side chain modifications contemplated by the present invention include modification of amino groups, such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidation with methylacetimidate; acetylation with acetic anhydride; carbamylation of amino groups with 2, 4, 6, trinitrobenzene sulfonic acid (TNBS); alkylation of amino groups with succinic anhydride and tetrahydronaphthalic anhydride; and pyridoxylation of lysine with pyridoxal-5'-phosphate followed by reduction with NaBH_4 .

The guanidino group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents, such as 2, 3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation via o-acylisourea formation followed by subsequent derivatisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods, such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of mixed disulphides with other thiol compounds; reaction with maleimide; maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulfonic acid, phenylmercury chloride,

2-chloromercuric-4-nitrophenol and other mercurials; carbamylation with cyanate at alkaline pH.

5 Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphonyl halides. Tryosine residues may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

10 Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

15 Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids.

20 The immunogenic compositions may be prepared as injectables, as liquid solutions or emulsions. The antigens and immunogenic compositions may be mixed with physiologically acceptable carriers which are compatible therewith. These may include water, saline, dextrose, 25 glycerol, ethanol and combinations thereof. The vaccine may further contain auxiliary substances, such as wetting or emulsifying agents or pH buffering agents, to further enhance their effectiveness. Vaccines may be administered by injection subcutaneously or 30 intramuscularly.

35 Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively,

other modes of administration including suppositories may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols and triglycerides. Oral formulations may include normally 5 employed incipients, such as pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

These compositions may take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 1 to 95% of the 10 immunogenic compositions of the present invention.

The immunogenic compositions are administered in a manner compatible with the dosage formulation, and in such amount as to be therapeutically effective, protective and immunogenic. The quantity to be 15 administered depends on the subject to the immunized, including, for example, the capacity of the subject's immune system to synthesize antibodies, and if needed, to produce a cell-mediated immune response. Precise amounts of antigen and immunogenic composition to be administered 20 depend on the judgement of the practitioner. However, suitable dosage ranges are readily determinable by those skilled in the art and may be of the order of micrograms to milligrams. Suitable regimes for initial administration and booster doses are also variable, but 25 may include an initial administration followed by subsequent administrations. The dosage of the vaccine may also depend on the route of administration and will vary according to the size of the host.

The concentration of antigen in an immunogenic 30 composition according to the invention is in general 1 to 95%. A vaccine which contains antigenic material of only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present 35 invention. Such combined vaccines contain, for example, material from various pathogens or from various strains

of the same pathogen, or from combinations of various pathogens.

Immunoassays

In one embodiment, the adjuvant mixtures of the present invention are useful for the production of immunogenic compositions that can be used to generate antigen-specific antibodies that are useful in the specific identification of that antigen in an immunoassay according to a diagnostic embodiment. Such immunoassays include enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the antigen-specific antibodies are immobilized onto a selected surface; for example, the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein, such as a solution of bovine serum albumin (BSA) or casein, that is known to be antigenically neutral with regard to the test sample may be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antigens onto the surface. The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This may include diluting the sample with diluents, such as BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 25° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution such as PBS/Tween, or a borate buffer.

Following formation of specific immunocomplexes between the antigen in the test sample and the bound antigen-specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation 5 may be determined by subjecting the immunocomplex to a second antibody having specificity for the antigen. To provide detecting means, the second antibody may have an associated activity, such as an enzymatic activity, that will generate, for example, a colour development upon 10 incubating with an appropriate chromogenic substrate. Quantification may then be achieved by measuring the degree of colour generation using, for example, a visible spectra spectrophotometer. In an additional embodiment, the present invention includes a diagnostic kit 15 comprising antigen-specific antibodies generated by immunization of a host with immunogenic compositions produced according to the present invention.

EXAMPLES

The above disclosure generally describes the present 20 invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of 25 equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

Example 1

30 This Example describes the preparation of synthetic peptides.

Peptides (Table 1) were synthesized using an ABI 430A peptide synthesizer and optimized t-Boc chemistry as described by the manufacturer, then cleaved from the 35 resin by hydrofluoric acid (HF). The peptides were purified by reversed-phase high performance liquid

chromatography (RP-HPLC) on a Vydac C4 semi-preparative column (1 x 30 cm) using a 10 to 50% acetonitrile gradient in 0.1% trifluoromethyl acetic acid (TFA) developed over 40 minutes at a flow rate of 2 mL/min. All 5 synthetic peptides (Table 1) were >95% pure as judged by analytical HPLC. Amino acid composition analyses of these peptides performed on a Waters Pico-Tag system were in good agreement with their theoretical compositions.

Example 2

10 This Example describes the synthesis of adjuvants. N-alkyl-N-glycosyl-carboxamides (N-(2-L-leucine-amino-2-deoxy- β -D-glucopyranosyl)-N-octadecyl-dodecanoic acid amide, BAY R1005 and its analogs) were prepared following the process disclosed in Lockhoff et al., U.S. 15 Patent No. 4,855,283. BAY R1005 and its analogs can be further purified by ion-exchange chromatography. The octadecyl ester of an aromatic amino acid (OTH) was prepared according to Moloney et al., US Patent No. 4,258,029. Fmoc-S-(2,3-bis(palmitoyloxy)-[2R]-propyl)-20 [R]-cysteine using the coupling procedure of Fmoc chemistry into a growing peptide chain and then acylated at the N-terminus by a palmitoyl group. TPC derivatives can be either tripalmitoyl-Cys-Ser-Ser-Asn-Ala (Ad) or tripalmitoyl-Cys-Ser-Glu-Glu-Glu (Ad-4), or 25 tripalmitoyl-Cys-Ser-Lys-Lys-Lys-Lys (Ad-2).

Example 3

This Example describes the formulation of adjuvants with an antigen.

30 The adjuvant BAY R1005, OTH or TPC derivatives were mixed with sterile distilled water or saline buffer using for example a sonicator for two to thirty minutes. The adjuvants were prepared on a laboratory scale as stock solutions of 10 mg/mL for BAY R1005, 1 mg/mL for OTH and TPC derivatives. The synthetic adjuvant stock solution 35 was added to an antigen to produce 1 mg/mL BAY R1005 or 200 μ g/mL OTH or TPC derivatives. The antigen may be

obtained by, for example, methods of peptide synthesis and recombinant techniques that are not explicitly described in this disclosure but are amply reported in the scientific literature and are within the scope of 5 those skilled in the art.

Example 4

This Example describes the preparation of adjuvant compositions and immunogenic compositions containing a mineral salt adjuvant and at least one other adjuvant.

10 A synthetic adjuvant may be prepared as described in Example 2 and the mineral salt adjuvant may be clinical grade aluminum phosphate obtainable from, for example, Connaught Laboratories Limited, Toronto Canada.

15 The immunogenic composition was prepared by first mixing BAY R1005 with sterile distilled water or saline buffer using a sonicator for two to thirty minutes. Ten mL of the desired amount (1 to 200 μ g per mL) of antigen absorbed onto 3.1 mg per mL of AlPO₄ suspension for 1 to 20 24 hr, was added to 1 mL BAY R1005 stock solution, and the solution was mixed gently for 30 minutes at room temperature.

Preparation of an HIV synthetic peptide immunogenic composition

25 A BAY R1005 stock solution of 10 mg/mL was prepared as described above. Ten mL of the desired amount (20 to 200 μ g per mL) of HIV synthetic peptides (Table 1) absorbed onto 3.1 mg per mL of AlPO₄ suspension for 1 to 30 24 hr, were then added to 1 mL BAY R1005 stock solution, and the solution mixed gently for 30 minutes at room temperature. The HIV synthetic peptide vaccine formulation was stored at 4°C for long term storage. The vaccine formulation was gently mixed for 10 minutes at room temperature before injecting into hosts.

Preparation of a flu vaccine formulation

35 A BAY R1005 stock solution of 10 mg/mL was prepared as described above. Ten mL solution containing twenty

human doses of flu split vaccine obtained commercially from Pasteur Merieux SV, Lyon, France, were added into 1 mL BAY R1005 stock solution. The mixture was vortexed for 10 minutes at room temperature. The emulsified flu 5 vaccine was then mixed with 3.1 mg per mL of AlPO₄ suspension for 1 to 24 hr, and then the vaccine formulation stored at 4°C.

Preparation of RSV peptide vaccine formulation

A BAY R1005 stock solution of 10 mg/mL was prepared 10 as described above. Ten mL of the desired amount (100 µg per mL) of RSV synthetic peptides (Table 1) absorbed onto 3.1 mg per mL of AlPO₄ suspension for 1 to 24 hr, were added to 1 mL BAY R1005 stock solution, and the solution mixed gently for 30 minutes at room temperature. The RSV 15 synthetic peptide vaccine formulation was stored at 4°C.

Preparation of PIV3 vaccine formulation

A BAY R1005 stock solution of 10 mg/mL was prepared as described above. Ten mL of the desired amount (0.3 to 20 3 µg per mL) of PIV3 subunit vaccine containing HN and F proteins absorbed onto 3.1 mg per mL of AlPO₄ suspension for 1 to 24 hr. The PIV3 subunit vaccine was prepared according to published International patent application WO 91/00104, assigned to the assignee hereof. The alum-absorbed PIV3 antigens were added to 1 mL BAY R1005 stock 25 solution, and the solution mixed gently for 30 minutes at room temperature. The PIV3 vaccine formulation was stored at 4°C.

Preparation of flu BHA vaccine formulation

A BAY R1005 stock solution of 10 mg/mL was prepared 30 as described above. Ten mL of the desired amount (0.5 to 10 µg per mL) of flu BHA subunit vaccine were absorbed onto 3.1 mg per mL of AlPO₄ suspension for 1 to 24 hr. The flu BHA subunit vaccine prepared according to Brand and Skehel (Nature New Biol. 1972, 238:145-147), was 35 provided by Dr. D. Burt of Connaught Laboratories Limited, Willowdale, Ont. Canada. The alum-absorbed flu

BHA was added to 1 mL BAY R1005 stock solution, and the solution mixed gently for 30 minutes at room temperature. The flu BHA vaccine formulation was stored at 4°C.

Preparation of pertussis toxoid vaccine formulation

5 A BAY R1005 stock solution of 10 mg/mL was prepared
as described above. Ten mL of the desired amount (1 to
20 µg per mL) of pertussis toxoid, prepared according to
Tan et al. U.S. Patent No. 4,997,915, assigned to the
assignee hereof, were absorbed onto 3.1 mg per mL of
10 AlPO₄ suspension for 1 to 24 hr. The alum-absorbed
pertussis toxoid was added to 1 mL of BAY R1005 stock
solution, and the solution mixed gently for 30 minutes at
room temperature. The pertussis toxoid vaccine
formulation was stored at 4°C.

15 Example 5

This Example describes the general immunization protocol used for testing adjuvant compositions and immunogenic compositions.

Guinea pig immunizations

20 Three guinea pigs were used. The animals were pre-bled at day 0 and then injected IM with 500 μ L of the formulation containing the desired amount of antigen, 1.5 mg of AlPO₄, and 500 μ g of immunodulators BAY R1005 or its derivatives on day 1, 14 and 29. Blood samples were
25 obtained on day 28, and animals were bled out on day 42. The antibody titres were assayed for peptide-specific IgG antibodies using an antigen specific enzyme-linked immunosorbent assay (ELISA). The functional antibody responses were measured using virus neutralization and/or
30 haemagglutination inhibition (HAI) assays and, for pertussis toxoid, the ability of antisera to inhibit induced CHO cell clustering was determined.

Mouse immunizations

35 Three to five mice were used. The animals were pre-
bled at day 0 and then injected IP with 200 μ L of the
formulation containing the desired amount of antigen,

0.6 mg of AlPO₄, and 200 µg of adjuvant BAY R1005 or its derivatives on day 1, 14 and 29. Blood samples were obtained on day 28, and animals were bled out on day 42.

The antibody titres were assayed for peptide-specific IgG antibodies using an antigen specific enzyme-linked immunosorbent assay (ELISA). The functional antibody responses were measured using virus neutralization and/or haemagglutination inhibition (HAI) assays.

Example 6

10 This Example describes an analysis of the immune response to immunogenic compositions.

Antigen-specific ELISAs

15 Microtiter wells (Nunc-Immunoplate, Nunc, Denmark) were coated with 200 ng of purified antigen (PT, HA, PIV3, HN and F) or 500 ng of individual peptides in 50 μ L of coating buffer (15mM Na₂CO₃, 35 mM NaHCO₃, pH 9.6) for 16 hr at room temperature. The plates were then blocked with 0.1% (w/v) BSA in phosphate buffer saline (PBS) for 30 minutes at room temperature. Serially diluted 20 antisera were added to the wells and incubated for 1 hr at room temperature. After removal of the antisera, the plates were washed five times with PBS containing 0.1% (w/v) Tween-20 and 0.1% (w/v) BSA. F(ab')₂ fragments from goat anti-rabbit, guinea pig, mouse, or human IgG 25 antibodies conjugated to horseradish peroxidase (Jackson ImmunoResearch Labs Inc., PA) were diluted (1/8,000) with washing buffer, and added onto the microtiter plates. After 1 hr incubation at room temperature, the plates were washed five times with the washing buffer. The 30 plates were then developed using the substrate tetramethylbenzidine (TMB) in H₂O₂ (ADI, Toronto). The reaction was stopped with 1N H₂SO₄ and the optical density was measured at 450 nm using a Titretek Multiskan II (Flow Labs., Virginia). Two irrelevant pertussis toxin 35 peptides NAD-S1 (19 residues) and S3(123-154) (32 residues) were included as negative controls in the

peptide-specific ELISAs. Assays were performed in triplicate, and the reactive titer of each antiserum was defined as the dilution consistently showing 2-fold increase absorbance value over those obtained from the 5 negative controls.

Haemagglutination inhibition (HAI) assays

The assay is based on the capacity of antisera capable of neutralizing either influenza virus or PIV3 to agglutinate red blood cells of guinea pigs (PIV3) or 10 chicken (flu virus). Red blood cells are added to the wells of a 96-well microtitration plate containing serial dilutions of antisera and a constant amount of virus. Following incubation, HAI titer is read by determining 15 the degree of haemagglutinin inhibition. The lowest dilution of antisera blocking haemagglutination is the endpoint titer. A reference sample with a known HAI is run in parallel.

Virus neutralization assays

The assay is based on the capacity of antisera to 20 inhibit PIV3 growth in Vero cells. To Vero cells grown on wells of a 96-well microtitration plate, serial dilutions of antisera and a constant amount of virus are added. Following incubation, VN titer of each antisera is read by the determination of 50% inhibition of 25 cytopathic effect caused by PIV3. The lowest dilution of antisera blocking the virus cytopathic effect is the endpoint titer. A reference sample with a known VN titer is run in parallel.

HIV-1 virus neutralization assays

30 The ability of antisera to neutralize HIV-1 was determined in a syncytia (multi-nuclei giant cells) inhibition assay. Ten μ L of serially diluted antiserum was added to the wells of a 96-well tissue culture plate. 5 - 10×10^3 HIV-1 infected CEM cells (in 50 μ L) were 35 then added to each well. 7×10^4 uninfected MOLT-4 cells (in 50 μ L) were then added to each well. The plates were

then incubated in a CO₂ incubator overnight. In samples where no syncytia were formed (i.e. functional, virus-neutralizing antibodies were present in the antiserum), these plates were incubated for a further 24 hours and 5 then reexamined for syncytia formation. The number of syncytia was then scored under an inverted microscope. The lowest dilution of antisera blocking 90% of virus syncytia formation is the endpoint titer. A reference sample with a known virus neutralising titer was run in 10 parallel.

Example 7

This Example describes the protocol that can be used for the generation of antigen-specific T-cell lines by immunogenic preparations of the present invention.

15 BALB/c (H-2^d) mice purchased from Charles River Animal Farm (Montreal, Canada) are individually primed subcutaneously with desired amount of amount of antigen (1 to 100 µg) emulsified with either BAY R1005 or its derivatives. The animals are boosted twice with the same
20 dose of immunogen at 3 week intervals. Ten days after the last boost, spleens of immunized mice are removed. Splenocytes are cultured at 6×10^5 cells per well in a final volume of 200 µL of RPMI 1640 medium (Flow Lab.) supplemented with 10% heat-inactivated fetal calf serum
25 (Gibco), 2 mM L-glutamine (Flow Lab.), 100 U/mL penicillin (Flow Lab.) and 5×10^{-5} M 2-mercaptoethanol (Sigma) in the presence of varying concentrations (1, 10 and 100 µg per mL) of antigen in 96-well plates (Nunc, Denmark). Cultures are kept in a humidified incubator in
30 the presence of 5% CO₂/air. Triplicate cultures are performed for each concentration of antigen. Five days later, 150 µL of 10% rat concanavalin A culture supernatant diluted in culture medium is added to the microtiter plate wells as a source of Interleukin-2 (IL-
35 2) to expand antigen-specific T-cells. Six days later, 150 µL of supernatant is removed from each microculture,

and 150 μ L of fresh IL-2 containing culture supernatant added to further expand and maintain the viability of the antigen-specific T-cells. After a further 6 day-incubation, the cells are washed three times, each time 5 with 200 μ L of culture medium.

Each set of cultures is then stimulated with the corresponding concentrations (1, 10 and 100 μ g per mL) of the antigen in the presence of 2×10^5 irradiated (1,500 rad) BALB/c spleen cells in a final volume of 200 μ L of 10 culture medium. Sixty μ L of supernatant are then removed from each microculture. The supernatants from each triplicate cultures set are pooled. All supernatants are assayed for IL-2, Interleukin-4 and Interferon-gamma (IFN- γ), using murine IL-2 and IL-4 ELISA kits purchased 15 from Endogen Inc. (MA, USA) respectively. Assay of IFN- γ can be done using a mouse IFN- γ ELISA kit supplied by Genzyme Corporation (MA, USA). Test culture supernatants can be assayed at 1 in 5 dilution according to the manufacturers' instructions.

20 **Example 8**

This Example describes the covalent linkage of BAY R1005 to a peptide.

N-(glutarylacylamido-2-deoxy- β -D-glucopyranosyl)-N-alkyl-carboxamide which can be used to covalently link 25 BAY R1005 derivatives to either a peptide or protein was synthesized as follows. To a solution of N-(2-amino-2-deoxy- β -D-glucopyranosyl)-N-alkyl-carboxamide (2 mmol) in dioxane (28 mL) was added di-isopropylethyl amine (8 mmol) and glutaric anhydride (12 mmol). The reaction 30 mixture was stirred overnight at room temperature under argon. Ammonium hydroxide (28 mL) was added to the mixture, and then it was stirred for an additional 18 hours. The product was formed as a precipitate which was filtered, and then redissolved in a solution containing 35 water and t-butanol (2 : 1). The solution was then acidified by the gradual addition of acetic acid (4 mL).

The solution was then lyophilized to afford the product in 73 % yield, mass spectroscopic analyses (FAB-HRMS) of N-(glutarylacylamido-2-deoxy- β -D-glucopyranosyl)-N-alkyl-carboxamide, C₄₃ H₈₃ N₂ O₈, calculated 755.6149; and found 5 755.6129.

Resin-bound side-chain protected CLTB-36 peptide was synthesized using F-moc chemistry as follows. Two hundred to 500 mg of resin carrying the N-Fmoc protected first amino acid residue was placed in a reaction vessel. 10 The resin was washed 4 times with DMF, then prewashed with a 50% solution of piperidine in DMF (5 mL for 1 minute) and deprotected with a 50% solution of piperidine in DMF (10 mL for 9 minutes). The resin was then washed with DMF (5 times, 10 mL each). The peptide resin was 15 then coupled with 5 equivalent of the desired Fmoc-protected amino acids activated with phosphonium hexafluorophosphate ester (pfpe) in the presence of DIEA at room temperature for 2 to 3 hr and washed with DMF (5 times, 10 mL each). After the final DMF washing step, an 20 aliquot was taken for a ninhydrine test. If the test was negative, one goes to step 1 for coupling of the next amino acid. If the test was positive or slightly positive, the coupling and DMF washing steps were repeated. 25 The N-(glutarylacylamido-2-deoxy- β -D-glucopyranosyl)-N-alkyl-carboxamide was conjugated to synthetic peptide CLTB-36 as follows: N-Hydroxysuccinimide (335 ug, 1.12 eq.) was added to a solution containing the glycolipid prepared as described 30 above (2.0 mg) and dicyclohexylcarbodiimide dissolved in dichloromethane (2 mL). The resulting mixture was then stirred for 4 hours at room temperature. The dicyclohexylurea was filtered and the resulting filtrate was evaporated to dryness. The dried active ester was 35 redissolved in DMF (0.1 mL) and was added into a peptide-resin containing side-chain protected CLTB-36 at molar

ratio of 1.1 to 1. The reaction mixture was stirred overnight at room temperature. The excess reagents were filtered and the peptide-resin was washed with 4 x 10 mL of dichloromethane. After drying, the peptide-resin was 5 treated with TFA to release lipidated CLTB-36 from resin. The crude lipidated peptide was further purified by HPLC using a C4 Vydac column (1 x 35 cm) with a acetonitrile gradient from 20 to 60% developed within 40 minutes at a flow rate 2 mL/minute. Amino acid composition analyses 10 of lipidated CLTB-36 performed on a Waters Pico-Tag system were in good agreement with their theoretical compositions, and the presence of fatty acids were confirmed by GC analyses of the acid hydrolysate.

The N-(glutarylacylamido-2-deoxy- β -D-glucopyranosyl-15 N-alkyl-carboxamide was conjugated to flu recombinant NP protein as follows:

N-Hydroxysuccinimide (335 ug, 1.12 eq.) was added to a solution containing the glycolipid prepared as described above (2.0 mg) and dicyclohexylcarbodiimide dissolved in 20 dichloromethane (2 mL). The resulting mixture was then stirred for 4 hours at room temperature. The dicyclohexylurea was filtered and the resulting filtrate was evaporated to dryness. The dried active ester (2.25 mg) was redissolved in DMF (0.1 mL) and was added into a 25 protein solution (2 mg rNP1 protein dissolved in 2 mL of 25 mM phosphate buffer, pH 7.8) at a molar ratio of 20 : 1. The reaction mixture was stirred overnight at 4°C, and then was dialysed against 4 x 4L of the phosphate buffer. The incorporation of N-(glutarylacylamido-2-30 deoxy- β -D-glucopyranosyl)-N-alkyl-carboxamide to flu recombinant NP was determined and confirmed using gas chromatography (GC) for lipid analyses of the acid hydrolysate (6 N of HCl for 2 hr at 110°C) of the modified protein.

35 The present invention has been exemplified by reference to particular examples and embodiments.

Numerous adaptations, variations and modifications may be made to the particular examples and embodiments without departing from the essence of the invention which is defined in the claims.

5

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides novel adjuvant compositions which are able to elicit an enhanced immune response against antigens and novel compounds comprising antigen covalently bonded to 10 a glycolipid analog. Modifications are possible within the scope of the invention.

Table 1
SYNTHETIC PEPTIDES USED IN THE STUDIES

PEPTIDES	AMINO ACID SEQUENCE	SEQ ID NO:
HIV peptides		
CLTB-36	GPKEPFRDYVDRFYKNRKRIHIGPGRAFYTTKN	1
CLTB-70	GPKEPFRDYVDRFYKNTRKSIIYIGPGAFHTTGR	2
CLTB-72	GPKEPFRDYVDRFYKNTRKRIRIQRGGRAFVTIGK	3
CLTB-74	GPKEPFRDYVDRFYKNTRKSITKGPGRVIVATGQ	4
CLTB-76	GPKEPFRDYVDRFYKNTRQSTPIGLGQALYTTRG	5
P24E-GP41C	GPKEPFRDYVDRFYKSLIEESQNQQEKNEQELLELDKWAS	6
RSV peptides		
RSV-F	QSYSIMSIIKEEVLAYAVQLPLPLYGVIDTP	7
RSV-FND2	PIVNKQSCSISNIETVIEFQQ	8
RSV-G1	TKQRQNKPSPSKPNNDHFHFEVFNFVPC	9
RSV-G2	CSNNPTCWAICKRIPNKKPGKKT	10
pertussis peptide		
69K-P1	PQPGPQPPQPPQPQPEAPAPQPPC	11
Hib peptides		
HIBP1-5E	NQITSALSTQQEFRDLKKYLP SKDKSVVSLQDRAC	12
TBP2-3	TVGKKTYQVEACCSNL SYVKFGM	13
Rubella virus peptide		
RV-EP27	PDPGDLVEYIMNYTGNQQSRWGLGSPNCHGPDWASPVCQRHSP	14
S. pneumoniae peptide		
PSP-AA	IKEIDESESEDYAKEGFRAP	15

TABLE 2
Guinea pigs antibody responses to synthetic peptides formulated with different adjuvants
Peptide-Specific Antibody Titre¹
Adjuvants used in the immunization

Peptide Immunogens ²	PBS	CFA	alum	BAY R1005	TPC	OTH
CLTB-36	400	256,000	10,000	72,800	3,200	6,400
CLTB-70	2,500	312,500	116,666	133,333	6,400	12,800
CLTB-72	2,333	312,500	37,500	45,800	3,200	6,400
CLTB-74	2,500	625,000	43,055	212,500	6,400	25,600
CLTB-76	1,833	625,000	9,166	45,833	3,200	6,400
P24E-GP41C	2,500	625,000	29,166	45,833	12,800	12,800
RSV-F	500	6,400	32,000	3,850	1,600	3,200
RSV-FND2	400	12,800	7,800	10,000	3,200	6,400
RSV-G2	1,280	128,000	31,500	3,200	1,600	ND ³
RSV-G1	1,600	315,000	128,000	31,500	6,400	ND
RV-EP27	400	128,000	12,800	800	6,400	25,600
HIBP1-5E	200	312,500	8,333	32,500	1,600	ND
69K-P1	800	10,000	32,500	32,500	1,600	ND
TBP2-3	400	12,500	43,333	32,500	ND	ND
PSP-AA	200	12,500	1,600	400	ND	ND

¹ Mean titer of three guinea pigs received three injections.

² All peptide immunogen except CLTB-36 are used 100 µg of peptide per dose formulated with different adjuvants. CLTB-36 is used 20 µg of peptide per dose.

³ Not done.

TABLE 3

Guinea pigs antibody responses to synthetic peptides formulated with different adjuvants

Peptide Immunogens ²	Peptide-Specific Antibody Titre ¹		
	alum	BAY R1005	BAY R1005 + alum
RSV-F	32,000	3,850	128,000
RSV-FND2	7,800	10,000	25,600
RV-EP27	12,800	800	64,000

¹ Mean titer of three guinea pigs received three injections.

² All peptide immunogens are used 100 μ g of peptide per dose formulated with different adjuvants.

TABLE 4

ANTIBODY RESPONSE TO CLTB-36 FORMULATED IN DIFFERENT ADJUVANTS

Antisera ¹	Dose (20 µg)	Average titers against		
		CLTB-36	CLTB-56 ²	Virus Syncytia-formation
Guinea pigs	alum	6,400	1,833	<10
	BAY R1005	62,500	4,333	15
	alum + BAY R1005	36,500	6,250	24
	BAY R1005 conjugated	20,833	5,833	23
	100 µg in alum ³	32,000	12,500	32

¹ Groups of guinea pigs (n = 3) were immunized with 20 µg of CLTB-36 emulsified in BAY R1005 and/or absorbed onto alum at day 1. Booster immunizations were at 2, 4 and 6 weeks with the same antigens. Blood samples were collected every 2 weeks after the third injection. Sera were analyzed by peptide-specific ELISAs, virus neutralization and syncytia formation inhibition assays.


² Peptide CLTB-56 is the B-cell epitope of CLTB-36 and has amino acid sequence of NKRKRIHIGPGRAYTTKN (SEQ ID NO: 16).

³ A 100 µg of CLTB-36 absorbed onto alum was used.

CLAIMS

What we claim is:

1. An adjuvant composition for modulating an immune response to an antigen administered to a host, the composition comprising:
 - (a) a mineral salt adjuvant; and
 - (b) at least one other adjuvant.
2. The composition of claim 1, wherein the mineral salt adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, calcium phosphate, zinc hydroxide and calcium hydroxide.
3. The composition of claim 2, wherein the at least one other adjuvant is selected from the group consisting of a glycolipid analog, an octadecyl ester of an amino acid and a lipoprotein.
4. The composition of claim 3, wherein the amino acid is an aromatic amino acid.
5. The composition of claim 4, wherein the aromatic amino acid is tyrosine.
6. The composition of claim 3, wherein the lipoprotein is a synthetic analog of an N-terminal portion of lipoprotein.
7. The composition of claim 3, wherein the glycolipid analog is a glycosylamide.
8. The composition of claim 7, wherein the glycosylamide has the formula,



in which

R1 denotes hydrogen or saturated or singly or multiply unsaturated alkyl radical having up to 50 carbon atoms;

X represents -CH₂-, -O- or -NH-,

R2 denotes hydrogen or saturated or singly or multiply unsaturated alkyl radical having up to 50 carbon atoms;

R3, R4, and R5, independently of one another, denotes hydrogen, or SO₄²⁻, or PO₄²⁻, or other negatively charged moiety, or -CO-R6, R6 being an alkyl radical having up to 10 carbon atoms;

R7 is L-alanyl, L-alpha-aminobutyryl, L-arginyl, L-asparaginyl, L-asparty, L-cysteinyl, L-glutamyl, L-glycyl, L-histidyl, L-hydroxypropyl, L-isoleucyl, L-leucyl, L-lysyl, L-methionyl, L-ornithinyl, L-phenylalanyl, L-prolyl, L-seryl, L-threonyl, L-tyrosyl, L-tryptophanyl, and L-lavyl or their D-isomers; and pharmaceutically acceptable salts thereof.

9. The composition of claim 8, wherein the glycosylamide is N - (2-deoxy-2-L-leucylamino- β -D-glucopyranosyl) - N -octadecyldodecanamide acetate.

10. The composition of claim 1, wherein the mineral salt is aluminum phosphate and the at least one other adjuvant is N - (2-deoxy-2-L-leucylamino- β -D-glucopyranosyl) - N - octadecyldodecanamide acetate.

11. An immunogenic composition for eliciting an immune response in a host, the composition comprising:

- (a) at least one antigen;
- (b) a mineral salt adjuvant; and
- (c) at least one other adjuvant.

12. The composition of claim 11, wherein the mineral salt adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, calcium phosphate, zinc hydroxide and calcium hydroxide.

13. The composition of claim 12, wherein the at least one other adjuvant is selected from the group consisting of a glycolipid analog, an octadecyl ester of an amino acid and a lipoprotein.


14. The composition of claim 13, wherein the amino acid is an aromatic amino acid.

15. The composition of claim 14, wherein the aromatic amino acid is tyrosine.

16. The composition of claim 13, wherein the lipoprotein is a synthetic analog of an N-terminal portion of lipoprotein.

17. The composition of claim 16, wherein the glycolipid analog is a glycosylamide.

18. The composition of claim 13, wherein the glycosylamide has the formula



in which

R1 denotes hydrogen or saturated or singly or multiply unsaturated alkyl radical having up to 50 carbon atoms;

X represents -CH₂-, -O- or -NH-;

R2 denotes hydrogen or saturated or singly or multiply unsaturated alkyl radical having up to 50 carbon atoms,

R3, R4, and R5, independently of one another, denotes hydrogen, or SO₄²⁻, or PO₄²⁻, or other negatively charged moiety, or acyl -CO-R6, R6 being an alkyl radical having up to 10 carbon atoms;

R7 is L-alanyl, L-alpha-aminobutyryl, L-arginyl, L-asparaginyl, L-asparty;, L-cysteinyl, L-glutamyl, L-glycyl, L-histidyl, L-hydroxypropyl, L-isoleucyl, L-leucyl, L-lysyl, L-methionyl, L-ornithinyl, L-phenylalanyl, L-prolyl, L-seryl, L-threonyl, L-tyrosyl, L-tryptophanyl, and L-lavyl or their D-isomers; and pharmaceutically acceptable salts thereof.

19. The composition of claim 18, wherein the glycosylamide is N -(2-deoxy-2-L-leucylamino- β -D-glucopyranosyl) - N -octadecyldodecanamide acetate.

20. The composition of claim 11, wherein the mineral salt is aluminum phosphate and the at least one other adjuvant is N -(2-deoxy-2-L-leucylamino- β -D-glucopyranosyl) - N - octadecyldodecanamide acetate.

21. The composition of claim 11, wherein the antigen is selected from the group consisting of microbial pathogens, bacteria, viruses, proteins, glycoproteins, lipoproteins, peptides, glycopeptides, lipopeptides, toxoids, carbohydrates and tumor-specific antigens.


22. The composition of claim 21, wherein the antigen comprises a peptide, glycopeptide or lipopeptide which includes an amino acid sequence corresponding to an antigenic determinant of an HIV, Rubella virus, Respiratory Syncytial Virus, Bordetella pertussis, Haemophilus influenzae or Streptococcus pneumoniae or a functional analog thereof.

23. The composition of claim 22, wherein the peptide includes an amino acid sequence shown in Table 1 or a functional analog thereof.

24. The composition of claim 21, wherein the antigen comprises a toxoid which is pertussis toxoid.

25. The composition of claim 21, wherein the protein is influenza haemagglutinin or a human parainfluenza virus subunit.

26. A method of modulating an immune response to an antigen comprising combining an antigen with the adjuvant composition of claim 1.
27. A method of generating an immune response in a host comprising administering thereto the composition of claim 11.
28. The method of claim 27, wherein the immune response is a humoral or a cell-mediated immune response.
29. A kit for preparing an immunogenic composition, comprising:
 - (a) means for containing a mineral salt adjuvant;
 - (b) means for containing at least one other adjuvant;
 - (c) means for containing at least one antigen; and
 - (d) means for combining the mineral salt adjuvant, at least one other adjuvant and at least one antigen to produce the immunogenic composition.
30. A compound comprising an antigen covalently linked to a glycolipid analog.
31. The compound of claim 30 wherein the glycolipid analog is a glycosylamide.
32. The compound of claim 31 wherein the glycosylamide has the formula



in which

R1 denotes hydrogen or saturated or singly or multiply unsaturated alkyl radical having up to 50 carbon atoms;

X represents -CH₂-, -O- or -NH-;

R2 denotes hydrogen or a saturated or singly or multiply unsaturated alkyl radical having up to 50 carbon atoms;

R3, R4, and R5, independently of one another, denotes hydrogen, or SO₄²⁻, or PO₄²⁻, or other negatively charged moiety, or -CO-R6, R6 being an alkyl radical having up to 10 carbon atoms;

R7 is L-alanyl, L-alpha-aminobutyryl, L-arginyl, L-asparaginyl, L-aspartyl, L-cysteinyl, L-glutamyl, L-glycyl, L-histidyl, L-hydroxypropyl, L-isoleucyl, L-leucyl, L-lysyl, L-methionyl, L-ornithinyl, L-phenylalanyl, L-prolyl, L-seryl, L-threonyl, L-tyrosyl, L-tryptophanyl, and L-lavyl or their D-isomers; and pharmaceutically acceptable salts thereof.

33. The compound of claim 32 wherein the glycosylamide is N-(2-deoxy-2-L-leucylamino- β -D-glycopyranosyl)-N-octadecylodecanamide acetate.

34. The compound of claim 30 wherein the antigen is selected from the group consisting of microbial pathogens, bacteria, viruses, proteins, glycoproteins, lipoproteins, peptides, glycopeptides, lipopeptides, toxoids, carbohydrates and tumor-specific antigens.

35. The compound of claim 34 wherein the antigen comprises a peptide, glycopeptide or lipopeptide which includes an amino acid sequence corresponding to an antigenic determinant of an HIV, Rubella virus, Respiratory Syncytial virus, Bordetella pertussis, Haemophilus influenzae or Streptococcus pneumoniae antigen or a functional analog thereof.

36. The compound of claim 35 wherein the peptide includes an amino acid sequence shown in Table I or a functional analog thereof.

37. The compound of claim 30 wherein the peptide is covalently linked to the glycolipid analog at a carboxy or amino terminus of the peptide.


38. The compound of claim 37 wherein the peptide and glycolipid analog are covalently linked by a cross-linker having a reactive functional group.

39. The compound of claim 38 wherein the reactive functional group is selected from the group consisting of maleimidyl, succinimidyl, 2-pyridyldithio, NH₂, SH, and -CO-R8 wherein R8 is -OH, N₃, -O-alkyl (C₁ - C₂), -OC₅F₅, H, Br or Cl.

40. An immunogenic composition for eliciting an immune response in a host, comprising:

- (a) a compound as claimed in claim 30, and
- (b) a mineral salt adjuvant.

1/9



SUBSTITUTE SHEET

2 / 9





FIG. 2.

SUBSTITUTE SHEET

3/9



SUBSTITUTE SHEET

4 / 9

CD1 MOUSE ANTIBODY RESPONSES TP TO ONE DOSE OF 0.3 ug OF
PIV3 HN & F PROTEINS MIXED WITH DIFFERENT ADJUVANTS





FIG. 4.
ADJUVANTS
ALUM/BAYR1005

SUBSTITUTE SHEET

5 / 9



SUBSTITUTE SHEET

6/9

GUINEA PIG ANTIBODY RESPONSES TO PERTUSSIS TOXOID FORMULATED IN DIFFERENT ADJUVANTS




FIG. 6.

SUBSTITUTE SHEET

7/9

GUINEA PIG ANTIBODY RESPONSES TO PERTUSSIS TOXOID FORMULATED IN DIFFERENT ADJUVANTS




FIG. 7.

SUBSTITUTE SHEET

8/9


GUINEA PIG RESPONSE TO CLTB36
FOLLOWING TWO 20 UG DOSES

FIG. 8.

SUBSTITUTE SHEET

9 / 9




FIG. 9.

SUBSTITUTE SHEET





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A3	(11) International Publication Number: WO 95/34308
A61K 33/06, 39/09, 39/10, 39/155, A61K 39/145, 39/20, 39/21			(43) International Publication Date: 21 December 1995 (21.12.95)
(21) International Application Number: PCT/CA95/00359		(74) Agent: STEWART, Michael, I.; Sim & McBurney, Suite 701, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).	
(22) International Filing Date: 15 June 1995 (15.06.95)		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(30) Priority Data: 08/261,194 16 June 1994 (16.06.94) US		(77) Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(60) Parent Application or Grant (63) Related by Continuation US 08/261,194 (CON) Filed on 16 June 1994 (16.06.94)		(88) Date of publication of the international search report: 23 May 1996 (23.05.96)	
(71) Applicant (for all designated States except US): CANNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, Willowdale, Ontario M2R 3T4 (CA).			
(72) Inventors; and (75) Inventors/Applicants (for US only): KANDIL, Ali [CA/CA]; 245 Park Home Avenue, Willowdale, Ontario M2R 1A1 (CA). JAMES, Olive, A. [CA/CA]; Apartment 609, 10 Martha Eaton Way, Toronto, Ontario M6M 5B3 (CA). CHONG, Pele [CA/CA]; 32 Estoril Street, Richmond Hill, Ontario L4C 0B6 (CA). KLEIN, Michel, H. [CA/CA]; 16 Munro Boulevard, Willowdale, Ontario M2P 1B9 (CA).			

(54) Title: ADJUVANT COMPOSITIONS COMPRISING A MINERAL SALT AND ANOTHER IMMUNOSTIMULATING COMPOUND

(57) Abstract

Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an adjuvanting effect on an antigen which is greater than the adjuvanting effect attainable by one of the adjuvants alone. An antigen is covalently bonded to a glycolipid analog to provide a discrete molecule which exhibits an enhanced adjuvanting effect on the antigen which is greater than the adjuvanting effect attainable in the absence of such covalent bonding.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 95/00359

A. CLASSIFICATION OF SUBJECT MATTER		IPC 6 A61K33/06 A61K39/09		A61K39/10 A61K39/20 A61K39/21		A61K39/145	
According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS SEARCHED							
Minimum documentation searched (classification system followed by classification symbols)							
IPC 6 A61K							
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched							
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)							
C. DOCUMENTS CONSIDERED TO BE RELEVANT							
Category	Citation of document, with indication, where appropriate, of the relevant passages			Relevant to claim No.			
X	DATABASE WPI Week 9323 Derwent Publications Ltd., London, GB; AN 93-185171 & JP,A,05 112 466 (SHIONOGI & CO) , 7 May 1993 see abstract --- EP,A,0 445 710 (BEHRINGWERKE) 11 September 1991 see the whole document --- US,A,4 855 283 (LOCKHOFF ET AL.) 8 August 1989 cited in the application --- -/-			1,2,11, 12,21, 26-28			
X				1,2,11, 12,21, 26-28			
A				-/-			
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.				<input checked="" type="checkbox"/> Patent family members are listed in annex.			
* Special categories of cited documents :							
A document defining the general state of the art which is not considered to be of particular relevance							
E earlier document but published on or after the international filing date							
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)							
O document referring to an oral disclosure, use, exhibition or other means							
P document published prior to the international filing date but later than the priority date claimed							
T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention							
X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone							
Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.							
& document member of the same patent family							
Date of the actual completion of the international search				Date of mailing of the international search report			
12 February 1996				10. 04. 96			
Name and mailing address of the ISA				Authorized officer			
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl. Fax (+ 31-70) 340-3016				Klaver, T			

INTERNATIONAL SEARCH REPORT

International Application No.

PC 95/00359

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US.A, 4 258 029 (MOLONEY ET AL.) 24 March 1981	
	cited in the application ---	
A	J. IMMUNOL., vol. 144, no. 12, 1990 pages 4798-4802,	
	A.NIXON-GEORGE ET AL. 'The adjuvant effect of stearyl tyrosine on a recombinant subunit hepatitis b surface antigen.'	
	cited in the application ---	
A	BIOLOGICALS, vol. 22, no. 1, 1994 pages 53-63,	
	R.K. GUPTA ET AL 'comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid.'	

A	PROG. LEUKOCYTE BIOL., vol. 9, 1989 pages 575-579,	
	K.G. STUENKEL ET AL. 'Synthetic glycolipids with immunopotentiating activity on humoral immunity: evaluation in vivo.'	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA95/00359

Box 1 Observations where claim or claims were found unsearchable (Continuation of Box 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. claims 1-29: An adjuvant composition, comprising a mineral salt, another adjuvant and optionally an antigen
2. claims 30-40: A novel antigen compound, and a composition containing it

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/ISA 95/00359

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-445710	11-09-91	DE-A- 4007315 AU-B- 653331 AU-B- 7271291 CA-A- 2037709 DE-D- 59100964 ES-T- 2049999 JP-A- 4217631 US-A- 5232690	12-09-91 29-09-94 12-09-91 09-09-91 17-03-94 01-05-94 07-08-92 03-08-93
US-A-4855283	08-08-89	DE-A- 3521994 AU-B- 564222 AU-B- 5897986 CA-A- 1289952 DE-A- 3683410 EP-A,B 0206037 IE-B- 58918 JP-B- 7116207 JP-A- 61293991 KR-B- 9311281	02-01-87 06-08-87 24-12-86 01-10-91 27-02-92 30-12-86 01-12-93 13-12-95 24-12-86 29-11-93
US-A-4258029	24-03-81	NONE	